Debiopharm, an independent biopharma based in Lausanne, Switzerland, operates with a different business model to many of its peers. The...
How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap
Listen to this article
Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.
Candid conversations with C-suite leaders.
More from Global Vision
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
• By
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
• By
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
